Krutika Sawant

Dr. Krutika Sawant


Research Focus & Metrics

Academic Career Length

57Years (1970-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
APAbhijeet P. Pandey
Abhijeet P. Pandey
KSKrutika Sawant
Krutika Sawant


1 August 2014 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
GJGarima Joshi
Garima Joshi
AKAbhinesh Kumar
Abhinesh Kumar
KSKrutika Sawant
Krutika Sawant

1 September 2021 in Journal of Controlled Release
Verified
Journal Article
Closed access
SGSaikat Ghosh
Saikat Ghosh
AJAnkit Javia
Ankit Javia
SSSaritha Shetty
Saritha Shetty
DBDenish Bardoliwala
Denish Bardoliwala
KMKuntal Maiti
Kuntal Maiti
SBSubhas Bhowmick
Subhas Bhowmick


1 January 2011 in Scientia Pharmaceutica
Verified
Journal Article
Open access
CDChetan Detroja
Chetan Detroja
SCSandip Chavhan
Sandip Chavhan
KSKrutika Sawant
Krutika Sawant
The objective of the present investigation was to enhance the oral bioavailability of practically insoluble Candesartan cilexetil [CC] by preparing nanosuspension. The nanosuspension was prepared by media milling using zirconium oxide beads and converted to solid state by spray drying. The spray dried nanosuspension of CC [SDCN] was evaluated for particle size, zeta potential, saturation solubility, crystallanity, surface morphology and dissolution behavior. SDCN showed particle size of 223.5±5.4 nm and zeta potential of -32.2±0.6 mV while saturation solubility of bulk CC and SDCN were 125±6.9 μg/ml and 2805±29.5 μg/ml respectively, showing more than 20 times increase in solubility. Differential Scanning Calorimetry [DSC] and X-ray diffraction [XRD] analysis showed that crystalline state of CC remained unchanged in SDCN. Dissolution studies in phosphate buffer pH 6.5 containing 0.7% Tween 20 showed that 53±5% of bulk drug dissolved in 15 min whereas SDCN was almost completely dissolved exhibiting higher dissolution velocity and solubility. Transmission electron microscopy [TEM] revealed that nanocrystals were not of uniform size, and approximately of oval shape. Pharmacodynamic study based on deoxycorticosterone acetate [DOCA] salt model was performed in rats to evaluate in-vivo performance, which showed 26.75±0.33% decrease in systolic blood pressure for nanosuspension while plain drug suspension showed 16.0±0.38% reduction, indicating that increase in dissolution velocity and saturation solubility leads to enhancement of bioavailability of SDCN when compared to bulk CC suspension. Thus, the results conclusively demonstrated a significant enhancement in antihypertensive activity of candesartan when formulated as nanosuspension.